View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Boston Scientific Corp: 1 director

A director at Boston Scientific Corp sold after exercising options/sold 160,901 shares at 93.495USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following Pen...

Our credit view of this issuer reflects its leading market positions and strong operating performance tempered by an ongoing appetite for acquisitions

Boston Scientific Corporation: Update to credit analysis following out...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its ongoing appetite for acquisitions

Boston Scientific Corporation: Key facts and statistics - LTM March 20...

A summary company profile, detailing Boston Scientific Corporation’s business operations and financial highlights.

Boston Scientific Corporation: Update to credit analysis following rat...

Our credit view of this issuer reflects its leading position in key markets and its broad product and geographic diversification, against its persistent appetite for acquisitions.

Boston Scientific Corporation: Update to credit analysis

Our credit view of this issuer reflects its significant scale, geographic diversification and strong organic growth track record in medical devices, tempered by its appetite for M&A

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch